Literature DB >> 10969931

Neurofibromatosis type 1 and precocious puberty.

R Virdis1, M Sigorini, A Laiolo, E Lorenzetti, M E Street, A R Villani, A Donadio, F Pisani, C Terzi, L Garavelli.   

Abstract

Since neurofibromatosis type 1 (NF1) is a well known cause of precocious puberty (PP), we reviewed 412 NF1 pediatric patients to evaluate the prevalence of PP, the association with optic pathway tumors (OPT), and other clinical, auxological and hormonal data. Thirty-one of 412 patients had OPT (7.5%), 10/412 PP (2.4%), and in seven of these PP was associated with OPT (7/31, 22.6%). OPT in patients with PP involved the chiasm in four patients, and the optic nerves alone in three patients. The age at the onset of puberty (or better at diagnosis) ranged from 5.2 to 7.5 yr in girls (n=6) and from 7.9 to 8.9 yr in boys (n=4). LHRH agonist therapy was used in only three children because in the others the predicted height at diagnosis was good, treatment was refused or the patients were referred to us too late. The three treated patients attained a final height within the familial range. In the untreated patients the progression of puberty was not too rapid and final height was slightly below the genetic target in four patients; however, three patients had a final height markedly below the familial range. In conclusion, the prevalence of PP is increased in children with NF1, and frequently but not exclusively is associated with OPT. Moreover, sexual precocity does not seem to be necessarily bound to chiasmatic OPT. Treatment seems to be useful in the children with younger age at the onset of puberty or with a progressive decline in predicted final height.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10969931     DOI: 10.1515/jpem.2000.13.s1.841

Source DB:  PubMed          Journal:  J Pediatr Endocrinol Metab        ISSN: 0334-018X            Impact factor:   1.634


  9 in total

1.  Precocious and accelerated puberty in children with neurofibromatosis type 1: results from a close follow-up of a cohort of 45 patients.

Authors:  Sara Lomelino Pinheiro; Joana Maciel; Daniela Cavaco; Ana Abrantes Figueiredo; Inês Lemos Damásio; Sara Donato; João Passos; Joana Simões-Pereira
Journal:  Hormones (Athens)       Date:  2022-10-21       Impact factor: 3.419

2.  Prevalence of Associated Endocrine Diseases in Patients with Neurofibromatosis Type 1.

Authors:  Aysha Alshahrani; Zainah Abuoliat; Awad Saad Alshahrani; Mohammed Ali Al Balwi
Journal:  Avicenna J Med       Date:  2022-02-18

3.  Precocious puberty: An experience from a major teaching hospital in Central Saudi Arabia.

Authors:  Huda A Osman; Nasir A M Al-Jurayyan; Amir M I Babiker; Hessah M N Al-Otaibi; Reem D H AlKhalifah; Sharifah D A Al Issa; Sarar Mohamed
Journal:  Sudan J Paediatr       Date:  2017

Review 4.  Central precocious puberty: current treatment options.

Authors:  Franco Antoniazzi; Giorgio Zamboni
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

5.  Familial male-limited precocious puberty in neurofibromatosis type I.

Authors:  Yvonne Yijuan Lim; Raymond Ming-En Chan; Kah Yin Loke; Cindy Weili Ho; Yung Seng Lee
Journal:  Eur J Pediatr       Date:  2013-08-28       Impact factor: 3.183

Review 6.  Central precocious puberty: Recent advances in understanding the aetiology and in the clinical approach.

Authors:  Luigi Maione; Claire Bouvattier; Ursula B Kaiser
Journal:  Clin Endocrinol (Oxf)       Date:  2021-04-20       Impact factor: 3.523

Review 7.  Optic glioma and precocious puberty in a girl with neurofibromatosis type 1 carrying an R681X mutation of NF1: case report and review of the literature.

Authors:  Mirjana Kocova; Elena Kochova; Elena Sukarova-Angelovska
Journal:  BMC Endocr Disord       Date:  2015-12-15       Impact factor: 2.763

8.  Double NF1 inactivation affects adrenocortical function in NF1Prx1 mice and a human patient.

Authors:  Karolina Kobus; Daniela Hartl; Claus Eric Ott; Monika Osswald; Angela Huebner; Maja von der Hagen; Denise Emmerich; Jirko Kühnisch; Hans Morreau; Frederik J Hes; Victor F Mautner; Anja Harder; Sigrid Tinschert; Stefan Mundlos; Mateusz Kolanczyk
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

9.  Predictive Modeling for Clinical Features Associated With Neurofibromatosis Type 1.

Authors:  Stephanie M Morris; Aditi Gupta; Seunghwan Kim; Randi E Foraker; David H Gutmann; Philip R O Payne
Journal:  Neurol Clin Pract       Date:  2021-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.